Revelation Biosciences PRIME Phase 1b CKD study hits endpoints; Gemini reduces inflammation in high-background patients

REVELATION BIOSCIENCES, INC.

Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.
In patients with high background inflammation (≈50%), Gemini significantly reduced IL-1β, TNF-α, IL-6, IL-10, IL-1RA vs placebo (p<0.01) through 7 days.
Gemini restored normal cellular response to LPS/HMGB1 stimuli in high-background PBMCs, reversing immunoparalysis (IL-1β p<0.0001).
Company scheduled End of Phase 1 meeting with FDA later in 2025 to discuss advancement.
40 patients enrolled across 5 dose cohorts in 3 US clinics; data webcast on Sept 10, 2025 at 8:30 AM ET.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.